Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16647905 | 0.84 | TRPA1 (0.42) | LOXL2LOXTRPA1KDM1AALOX5AP | |
| Hydrochloric Acid SCHEMBL16635002 | 0.83 | TRPA1 (0.41) | LOXL2LOXTRPA1ALOX5APFEN1 | |
| SCHEMBL16634927 | 0.79 | TRPA1 (0.45) | LOXL2TRPA1 | |
| SCHEMBL21716472 | 0.74 | GPBAR1 (0.33) | ALOX5APFEN1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24635124 | 0.74 | LOXL2 (0.41) | LOXL2LOX | |
| SCHEMBL16635649 | 0.74 | TRPA1 (0.40) | TRPA1 | |
| SCHEMBL18233502 | 0.72 | LOXL2 (0.44) | LOXL2LOXTRPA1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29411292 | 0.72 | TRPA1 (0.39) | LOXL2LOXTRPA1 | |
| SCHEMBL16823671 | 0.72 | IDO1 (0.38) | LOXL2LOX | |
| Hydrochloric Acid SCHEMBL18185602 | 0.70 | IDO1 (0.39) | LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | LOXL2 2972/4885LOX 3601/4885TRPA1 1/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | LOXL2 2972/4885LOX 3601/4885TRPA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.